共 50 条
- [21] Biomarkers predictive of response to enfortumab vedotin (EV) treatment in advanced urothelial cancer (aUC).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)Jindal, TanyaZhang, LiChou, JonathanShui, DavidPorten, Sima P.Wong, Anthony C.Chan, EmilyStohr, Bradley A.de Kouchkovsky, IvanBorno, HalaBose, RohitKwon, Daniel H.Desai, ArpitaHuang, Franklin W.Aggarwal, Rahul RajSmall, Eric JayFong, LawrenceFriedlander, Terence W.Koshkin, Vadim S.
- [22] Enfortumab vedotin and pembrolizumab: redefining the standard of care for previously untreated advanced urothelial cancerFUTURE ONCOLOGY, 2025,Sternschuss, MichalRosenberg, Jonathan E.
- [23] Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinomaANNALS OF ONCOLOGY, 2021, 32 : S710 - S711Rosenberg, J. E.Powles, T.Sonpavde, G. P.Loriot, Y.Duran, I.Lee, J. L.Matsubara, N.Vulsteke, C.Castellano, D.Mamtani, R.Sridhar, S. S.Pappot, H.Gurney, H. P.Bedke, J.Van der Heijden, M. S.Campbell, M.Wu, C.Matsangou, M.Petrylak, D. P.
- [24] Genomic profiling of a clinically annotated cohort of locoregionally advanced head and neck cancers (HNC) treated with definitive chemoradiotherapyJOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Seiwert, Tanguy Y.Keck, Michaela K.Zuo, ZhixiangKhattri, ArunBrown, ChristopherStricker, ThomasRieke, DamianLingen, Mark W.Cohen, Ezra E. W.White, Kevin P.Vokes, Everett E.
- [25] Phase 2 Trial of Enfortumab Vedotin in Patients With Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma in ChinaCANCER MEDICINE, 2024, 13 (21):Li, SimingShi, YanxiaDong, HaiyingGuo, HongqianXie, YuSun, ZhongquanZhang, XiaopingKim, EricZhang, JunLi, YueXu, ChenmingKadeerbai, HaishanLee, SueGorla, SeemaGuo, JunSheng, Xinan
- [26] Primary results of EV-301: A phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial carcinoma.JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)Powles, ThomasRosenberg, Jonathan E.Sonpavde, GuruLoriot, YohannDuran, IgnacioLee, Jae-LyunMatsubara, NobuakiVulsteke, ChristofWu ChunzhangCampbell, Mary S.Matsangou, MariaPetrylak, Daniel Peter
- [27] EV-103: Enfortumab vedotin plus pembrolizumab and/or chemotherapy for locally advanced or metastatic urothelial cancer.JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Hoimes, Christopher J.Rosenberg, Jonathan E.Petrylak, Daniel PeterCarret, Anne-SophieMelhem-Bertrandt, AmalFlaig, Thomas W.
- [28] Study EV-103: New randomized cohort testing enfortumab vedotin as monotherapy or in combination with pembrolizumab in locally advanced or metastatic urothelial cancer.JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)Mar, NataliyaFriedlander, Terence W.Hoimes, Christopher J.Flaig, Thomas W.Bilen, Mehmet AsimBalar, Arjun VasantHenry, ElizabethSrinivas, SandyRosenberg, Jonathan E.Petrylak, Daniel PeterBurgess, Earle FrederickMerchan, Jaime R.Tagawa, Scott T.Carret, Anne-SophieSteinberg, Joyce LetaChaney, Marya F.Milowsky, Matthew, I
- [29] EV-301: An open-label, randomized phase III study to evaluate enfortumab vedotin versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC)ANNALS OF ONCOLOGY, 2018, 29Petrylak, D. P.Rosenberg, J.Duran, I.Loriot, Y.Sonpavde, G.Wu, C.Gartner, E.Melhem-Bertrandt, A.Powles, T.
- [30] Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus ChemotherapyEUROPEAN UROLOGY, 2024, 85 (06) : 574 - 585Rosenberg, Jonathan E.Mamtani, RonacSonpavde, Guru P.Loriot, YohannDuran, IgnacioLee, Jae-LyunMatsubara, NobuakiVulsteke, ChristofCastellano, DanielSridhar, Srikala S.Pappot, HelleGurney, HowardBedke, Jensvan der Heijden, Michiel S.Galli, LucaKeam, BhumsukMasumori, NaoyaMeran, JohannesO'Donnell, Peter H.Park, Se HoonGrande, EnriqueSengelov, LisaUemura, HirojiSkaltsa, KonstantinaCampbell, MaryMatsangou, MariaWu, ChunzhangHepp, ZsoltMckay, CarolinePowles, ThomasPetrylak, Daniel P.